Eurofins Successfully Prices New €500M 7.5-Year Senior Unsecured Bonds

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:

Eurofins (Paris:ERF):

Eurofins Scientific (EUFI.PA, rated Baa3/stable by Moody’s and BBB-/stable by Fitch, “Eurofins”), a global leader in bioanalytical testing, announces that it has successfully raised €500m in its latest senior unsecured Euro-denominated public bond issuance (the “Bonds”). The Bonds have a 7.5-year maturity (due on 5 February 2033) and will bear an annual fixed rate coupon of 3.875%. The transaction was well received and was more than 8x over-subscribed.

As communicated on 23 July 2025, the proceeds of the New Bond will be used to finance Eurofins’ planned acquisition of related party-owned sites in the second half of 2025 as well as for general corporate purposes.

Comment from the CEO, Dr Gilles Martin: “We are very pleased with the results of our latest public bond issuance. This is a solid vote of confidence from investors in our approach to owning sites of long-term strategic interest to Eurofins and supports our objective of being the most productive, digital, innovative and customer-centric network of laboratories in the end markets and regions we serve.”

The Bonds will be listed from their issue date (5 August 2025) on the regulated market of the Luxembourg stock exchange (ISIN XS3135157298). The Bonds are not registered under the US Securities Act of 1933 as amended (the “Securities Act”) and may not be offered or sold (i) in the United States (as such term is defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from such registration nor (ii) in any other jurisdiction where it is unlawful to do so.

Notes to Editors:

For more information, please visit www.eurofins.com.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. The Eurofins Scientific SE network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

With over 65,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.

Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.

The Eurofins network has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, its companies draw on the latest developments in the field of biotechnology and analytical chemistry to offer their clients unique analytical solutions.

Shares in Eurofins Scientific SE are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).

Until it has been lawfully made public widely by Eurofins Scientific SE through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific SE’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific SE disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.